Carvalho Laura M L, Ferreira Cláudia N, Candido Ana L, Reis Fernando M, Sóter Mirelle O, Sales Mariana F, Silva Ieda F O, Nunes Fernanda F C, Gomes Karina Braga
Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Colégio Técnico, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Arch Gynecol Obstet. 2017 Oct;296(4):617-621. doi: 10.1007/s00404-017-4471-0. Epub 2017 Aug 9.
The objective of this study was to evaluate the levels of total microparticles (MPs) and microparticles-expressing tissue factor (TFMPs) in women with polycystic ovarian syndrome (PCOS) who use metformin comparing to those who do not take metformin.
We quantified total MPs and TFMPs in the plasma of 50 patients with PCOS-13 of these women used metformin (850 mg 2×/day during at least 6 months) and the other 37 did not. For this purpose, the microparticles (MPs) were purified by differential centrifugation of the plasma and, subsequently, by flow cytometry, using annexin-V and CD142 as markers.
Total MPs levels were lower in treated patients (59.58 ± 28.43 MPs/µL) when compared to untreated group (97.32 ± 59.42; p = 0.033). Plasma levels of TFMPs were also significantly lower in the group of patients who used metformin (1.10 ± 0.94 MPs/µL) when compared to untreated patients (2.20 ± 1.42 MPs/µL) (p = 0.003).
Considering that metformin reduced the levels of total MPs and TFMPs, our results suggest that this mechanism could be involved in the antithrombotic metformin effect, corroborating with the indication of this drug in the PCOS treatment.
本研究的目的是评估使用二甲双胍的多囊卵巢综合征（PCOS）女性与未服用二甲双胍的女性相比，其循环血中总微粒（MPs）和表达组织因子的微粒（TFMPs）水平。
我们对50例PCOS患者血浆中的总MPs和TFMPs进行了定量分析，其中13例女性使用二甲双胍（850mg，每日2次，至少服用6个月），另外37例未使用。为此，通过血浆差速离心法纯化微粒（MPs），随后使用膜联蛋白-V和CD142作为标记物，通过流式细胞术进行检测。
与未治疗组相比，治疗组患者的总MPs水平较低（59.58±28.43 MPs/μL）（97.32±59.42；p = 0.033）。使用二甲双胍的患者组血浆TFMPs水平也显著低于未治疗患者（1.10±0.94 MPs/μL）（2.20±1.42 MPs/μL）（p = 0.003）。
鉴于二甲双胍降低了总MPs和TFMPs的水平，我们的结果表明，这一机制可能参与了二甲双胍的抗血栓作用，这与该药物在PCOS治疗中的应用指征相符。
